导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.02% | 1403/4773 |
| 近一周 | 2.45% | 5/5458 |
| 近一月 | 7.30% | 32/5421 |
| 近一季 | 5.23% | 282/5205 |
| 近半年 | 7.84% | 617/4920 |
| 近一年 | 4.19% | 1908/4361 |
| 近两年 | 44.87% | 1697/2954 |
| 近三年 | 54.01% | 503/2253 |
| 成立以来 | 42.61% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.89% 2956/4961 |
-8.54% 3890/5312 |
- - |
- - |
| 2025 | 11.69% 2733/4813 |
2.75% 1277/3635 |
12.36% 100/4076 |
-8.78% 4060/4524 |
6.06% 383/4813 |
| 2024 | 41.81% 9/3463 |
10.66% 45/2808 |
7.23% 95/3014 |
13.16% 2229/3129 |
5.61% 585/3463 |
| 2023 | -2.37% 578/2656 |
-2.58% 2019/2280 |
2.20% 156/2385 |
5.12% 98/2515 |
-6.72% 1889/2655 |
| 2022 | -4.44% 94/2207 |
2.43% 54/1919 |
-1.46% 1727/2016 |
-8.50% 204/2113 |
3.47% 690/2208 |
| 2021 | -0.97% 773/1822 |
10.64% 31/1255 |
-2.70% 1226/1330 |
-7.43% 1052/1466 |
-0.63% 1261/1822 |
| 2020 | - - |
- - |
- - |
- - |
- - |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 天弘中证银行ETF VS. 长安沪深300非周期A(740101) |